文献速递精神分裂症与精神病性障碍

氨吡啶对工作记忆的影响:基于基因组导向药物重定位方法的随机对照试验

The effect of fampridine on working memory: a randomized controlled trial based on a genome-guided repurposing approach.
PubMed 文献 · Mol Psychiatry · 2024-11-08

该研究通过基因组导向药物重定位方法筛选出氨吡啶,并在43名健康年轻成人中开展双盲、随机、安慰剂对照交叉试验,评估重复给药3.5天(10 mg每日两次)对工作记忆(3-back d-prime)的影响。结果显示无显著主效应(Wilcoxon P=0.87,r=0.026),但基线表现较低者重复服用氨吡啶后工作记忆表现高于安慰剂(rs=-0.37,P=0.014,n=43),且氨吡啶降低静息运动阈值(F(1,37)=5.31,P=0.027,R2β=0.01)。

要点

  • 在43名健康年轻成人中,氨吡啶10 mg每日两次重复给药3.5天对工作记忆无显著主效应(Wilcoxon P=0.87,r=0.026)。
  • 基线表现较低者重复服用氨吡啶后工作记忆表现高于安慰剂(rs=-0.37,P=0.014,n=43)。
  • 氨吡啶降低静息运动阈值(F(1,37)=5.31,P=0.027,R2β=0.01),提示皮层兴奋性增加。

核心结论

  • 氨吡啶增强低表现个体工作记忆并增加脑兴奋性的能力,提示其治疗工作记忆缺陷的潜在价值。

研究设计与样本

  • 随机、双盲、安慰剂对照交叉试验,纳入43名健康年轻成人,比较氨吡啶10 mg每日两次重复给药3.5天与安慰剂。
  • 研究基于基因组导向药物重定位方法筛选出氨吡啶作为调节工作记忆的候选药物。

主要发现

  • 工作记忆(3-back d-prime,主要结局)无显著主效应(Wilcoxon P=0.87,r=0.026),与基线认知表现无关。
  • 基线表现较低与重复服用氨吡啶后工作记忆表现高于安慰剂相关(rs=-0.37,P=0.014,n=43)。
  • 重复服用氨吡啶降低静息运动阈值(非行为次要结局;F(1,37)=5.31,P=0.027,R2β=0.01),提示皮层兴奋性增加并与认知功能相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Working memory (WM), a key component of cognitive functions, is often impaired in psychiatric disorders such as schizophrenia. Through a genome-guided drug repurposing approach, we identified fampridine, a potassium channel blocker used to improve walking in multiple sclerosis, as a candidate for modulating WM. In a subsequent double-blind, randomized, placebo-controlled, crossover trial in 43 healthy young adults (ClinicalTrials.gov, NCT04652557), we assessed fampridine's impact on WM (3-back d-prime, primary outcome) after 3.5 days of repeated administration (10 mg twice daily). Independently of baseline cognitive performance, no significant main effect was observed (Wilcoxon P = 0.87, r = 0.026). However, lower baseline performance was associated with higher working memory performance after repeated intake of fampridine compared to placebo (rs = -0.37, P = 0.014, n = 43). Additionally, repeated intake of fampridine lowered resting motor threshold (F(1,37) = 5.31, P = 0.027, R2β = 0.01), the non-behavioral secondary outcome, indicating increased cortical excitability linked to cognitive function. Fampridine's capacity to enhance WM in low-performing individuals and to increase brain excitability points to its potential value for treating WM deficits.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Papassotiropoulos A, Freytag V, Schicktanz N, et al. The effect of fampridine on working memory: a randomized controlled trial based on a genome-guided repurposing approach. Mol Psychiatry. 2024. PMID: 39516710. doi:10.1038/s41380-024-02820-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。